Iron Horse to raise up to $10 mln Series A

By Iris Dorbian — 2 weeks ago

Avalon Ventures and GlaxoSmithKline have launched Iron Horse Therapeutics, which will receive up to $10 million in Series A funding. The seventh company to be formed by the Avalon/GSK partnership, Iron Horse is focused on developing new treatments for ALS.


Atreca grabs $56 mln Series A

By Iris Dorbian — 3 weeks ago

Redwood City, California-based biotech company Atreca Inc has closed $56 million in Series A funding. The investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline. Brookline Group LLC was the placement agent. PRESS RELEASE REDWOOD CITY, Calif.–(BUSINESS WIRE)–Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding […]


DDF launches $100 mln fund focused on treating dementia

By Iris Dorbian — 1 month ago

The Dementia Discovery Fund, which focuses on developing new dementia treatments, has raised $100 million. DDF’s backers include UK Government’s Department of Health, Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda. SV Life Sciences is managing the fund.


GSK buys GlycoVaxyn for $212 mln

By Luisa Beltran — 10 months ago

Sofinnova Partners has sold GlycoVaxyn to GlaxoSmithKline for $212 million. Schlieren, Switzerland-based GlycoVaxyn develops conjugate vaccines to treat bacterial infections. GSK was a minority investor of GlycoVaxyn.


Atopix picks up funding from SR One

By Iris Dorbian — 1 year ago

Atopix has received an undisclosed investment from SR One, the corporate venture capital arm of GlaxoSmithKline. Also, the company has added Dr. Deborah Harland, a partner at SR One, to its board of directors. Based in the UK, Atopix is a biopharmaceutical company focused on treating allergic disease.


RuiYi nets $15 mln Series B funds

By Iris Dorbian — 2 years ago

Sino-American biotech company RuiYi said Thursday that it has raised $15 million in Series B financing. The investors were 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.


Epizyme Files for an IPO

By Connie Loizos — 3 years ago

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.


OncoMed Promotes

By Angela Sormani — 4 years ago

OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has promoted Jakob Dupont, formerly vice president, clinical research to senior vice president and chief medical officer. Privately-held, OncoMed’s investors include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay […]


Amplimmune Signs Big Deal with GSK

By PEHub Administrator — 5 years ago

Amplimmune has signed a drug development deal with GlaxoSmithKline that includes a $23 million up-front payment and up to $485 million in milestone payments. The agreement relates to PD-1 targeting therapies that may help treat cancer and other diseases. Rockville, Md.-based Amplimmune has raised $20 million from InterWest Partners and Wellcome Trust.